Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring | WHS 2021 Virtual Meeting
As a Platinum Sponsor for this year's conference, Organogenesis will present an
Other research highlights include:
- A podium presentation, “Effect of Dehydrated Amnion Chorion Membranes on Mesenchymal Stem Cells In Vitro,” presented by
Katrina Harmon, PhD. The presentation will take place on May 12during Session 1C of the conference from 12-1 p.m. ET.
- A video presentation that will highlight the poster, “A Comparative Effectiveness Research Study of a Native Type I Collagen Matrix plus Polyhexamethylene Biguanide Antimicrobial and a Cryopreserved Cadaveric Skin Allograft for Use in Venous Leg Ulcers – A Non-Inferiority Analysis.” One of only 10 posters selected for exhibition during the Virtual Poster Grand Rounds session, the video presentation will be led by
Mike Sabolinski, MD. The accredited session will take place on May 14at 5:50 ET.
Visitors to the Organogenesis virtual exhibit booth will have the opportunity to participate in a live Q&A with a Tissue Regeneration Specialist about the Company’s innovative product solutions.
“Organogenesis’ rich heritage of trusted innovation is built on efficacy and ongoing investment in clinical and real-world data, as evidenced by this latest body of research supporting the use of our products across the spectrum of wound care,” said
POSTER PRESENTATIONS OF INTEREST INCLUDE:
A Comparative Effectiveness Research Study of a Native Type I Collagen Matrix plus Polyhexamethylene Biguanide Antimicrobial and a Cryopreserved Cadaveric Skin Allograft for Use in Diabetic Foot Ulcers – A Non-Inferiority Analysis
Thibodeaux KT, Sabolinski ML
A Comparative Effectiveness Research Study of a Bilayered Living Cellular Construct and a Cryopreserved Cadaveric Skin Allograft for Use in Venous Leg Ulcers
Alvarez OM, Sabolinski ML, Archambault T
Effectiveness of a Native Type I Collagen Matrix Plus Polyhexamethylene Biguanide (PHMB) Antimicrobial in the Treatment of Pressure Injuries in a Real-World Setting
Menack MJ, Thibodeaux K, Trabanco C, Sabolinski M
Harmon K, McQuilling JP, Mowry KC
In Vivo Evaluation of
McQuilling JP, Kammer M, Kimmerling K, Mowry KC
Clinical Trial Evaluating Changes in the Wound Microenvironment in Patients with VLUs Treated with a Hypothermically Stored Amniotic Membrane
McQuilling JP, Fulton J, Carter MJ, Patel K, Doner B, Serena L, Serena TE, Mowry KC
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts for future events. Forward-looking statements may be identified by the use of words such as "will," "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," "extend," "continue" and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. Important factors that could cause actual outcomes to differ materially from those indicated by these forward-looking statements include risks and uncertainties described in the Company’s Annual Report on Form 10-K for the year ended
Press and Media Inquiries:
Lori Freedmanlfreedman@organo.com Investor Inquiries: Westwicke Partners Mike Piccinino, CFA OrganoIR@westwicke.com 443-213-0500
Source: Organogenesis Holdings Inc.